Compare CWAN & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CWAN | STVN |
|---|---|---|
| Founded | 2004 | 1949 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Containers/Packaging |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 4.2B |
| IPO Year | 2021 | 2021 |
| Metric | CWAN | STVN |
|---|---|---|
| Price | $23.23 | $15.18 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 4 |
| Target Price | $25.09 | ★ $25.13 |
| AVG Volume (30 Days) | ★ 6.6M | 574.4K |
| Earning Date | 05-21-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 0.41% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $731,368,000.00 | N/A |
| Revenue This Year | $31.78 | $10.26 |
| Revenue Next Year | $18.18 | $10.02 |
| P/E Ratio | ★ N/A | $27.15 |
| Revenue Growth | ★ 61.88 | N/A |
| 52 Week Low | $15.74 | $13.91 |
| 52 Week High | $27.76 | $28.00 |
| Indicator | CWAN | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 42.96 | 43.89 |
| Support Level | $23.22 | $14.03 |
| Resistance Level | $24.33 | $17.14 |
| Average True Range (ATR) | 0.18 | 0.88 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 35.38 | 30.91 |
Clearwater Analytics describes its mission as aiming to be the world's most trusted and comprehensive technology platform for the entire investment cycle. Clearwater has historically focused on back-office functions such as investment accounting, but with acquisitions such Enfusion, Beacon, and Bistro, the firm has broadened its focus with front-office and middle-office capabilities. Clearwater primarily serves insurance companies, asset managers, hedge funds, and corporate treasuries. Pro forma for Enfusion, about 76% of Clearwater's revenue is generated in the US.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.